LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

LLY

1,032.74

-1.19%↓

JNJ

205.41

+0.03%↑

ABBV

230.3

+2.63%↑

UNH

340.48

+4.8%↑

AZN

90.84

+0.7%↑

Home・Stock List・Pliant Therapeutics Inc

Pliant Therapeutics Inc

Closed

1.53 2

Buy Sell

Overview

Share price change

24h

Current

Min

1.47

Max

1.55

Key metrics
By Trading Economics
Income	17M -26M
EPS	-0.43
Profit margin	-2,190.837
Employees	171
EBITDA	19M -23M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+96.08% upside

Market Stats
By TradingEconomics
Market Cap	-8.5M 94M
Previous open	-0.47
Previous close	1.53

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

1.43 / 1.6 Support & Resistance

Pliant Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

3 Dec 2025, 23:21 UTC

Earnings

Acquisitions, Mergers, Takeovers

EQB to Buy Loblaw Unit PC Financial for About $573.5 Million -- Update

3 Dec 2025, 23:14 UTC

Acquisitions, Mergers, Takeovers

EQB to Buy PC Financial From Loblaw for About $573.5 Million

3 Dec 2025, 22:01 UTC

Major Market Movers

Costco Wholesale Reports Higher Monthly Sales

3 Dec 2025, 21:38 UTC

Earnings

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500 Million

3 Dec 2025, 23:59 UTC

Market Talk

Australian Coal Prices Seen Having Recovered Well -- Market Talk

3 Dec 2025, 23:49 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

3 Dec 2025, 23:49 UTC

Market Talk

HSBC Chair Appointment Unlikely to Have Material Operational Impact -- Market Talk

3 Dec 2025, 23:49 UTC

Market Talk

Nikkei May Decline Amid Caution Over U.S. Labor Market -- Market Talk

3 Dec 2025, 23:13 UTC

Market Talk

Australian Treasurer Says Economy Not On Drip of Govt Spending -- Market Talk

3 Dec 2025, 23:10 UTC

Earnings

Salesforce Raises Forecast as Agentforce Sales Top $500M -- Update

3 Dec 2025, 23:08 UTC

Market Talk

Goodman's New Bull Sees Profit Upgrade on Cards -- Market Talk

3 Dec 2025, 23:06 UTC

Acquisitions, Mergers, Takeovers

EQB to Buy Loblaw Unit PC Financial for About $573.5M -- Update

3 Dec 2025, 22:59 UTC

Acquisitions, Mergers, Takeovers

EQB to Buy PC Financial From Loblaw for About $573.5M

3 Dec 2025, 22:45 UTC

Market Talk

WiseTech Investor Day Increases Bull's Confidence -- Market Talk

3 Dec 2025, 22:20 UTC

Earnings

Salesforce CEO: 9,500 of 18,500 Total Closed Agentforce Deals Are Paid

3 Dec 2025, 22:19 UTC

Earnings

Salesforce CEO: Six Out of 10 Biggest Deals in 3Q Came from Agentforce

3 Dec 2025, 22:17 UTC

Earnings

Salesforce Working to Add Voice to Agentforce, CEO Says

3 Dec 2025, 22:16 UTC

Earnings

Salesforce CEO: Williams-Sonoma's Agentforce Makes Up 60% of Customer Chats

3 Dec 2025, 22:15 UTC

Earnings

Salesforce CEO: Agentforce ARR Was $540M in 3Q

3 Dec 2025, 22:10 UTC

Acquisitions, Mergers, Takeovers

EQB: Will Enter Into a Long-Term Strategic Relationship With Loblaw >EQB.T

3 Dec 2025, 22:09 UTC

Acquisitions, Mergers, Takeovers

EQB: Agreed to Acquire PC Fincl From Loblaw >EQB.T

3 Dec 2025, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

3 Dec 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

3 Dec 2025, 21:49 UTC

Earnings

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 Dec 2025, 21:23 UTC

Earnings

Salesforce Raises Revenue Forecast as Agentforce Sales Top $500M

3 Dec 2025, 21:19 UTC

Earnings

Salesforce Reports Mounting Profits. The Stock Is Rising. -- Barrons.com

3 Dec 2025, 21:06 UTC

Earnings

Salesforce Reports Mixed Earnings. The Stock Is Rising. -- Barrons.com

3 Dec 2025, 21:04 UTC

Earnings

Salesforce Sees Profitable Growth Framework Target of 50 by FY30 >CRM

3 Dec 2025, 21:04 UTC

Earnings

Salesforce Targets $60 B Plus Organic Rev by FY30 >CRM

3 Dec 2025, 21:03 UTC

Earnings

Salesforce Raises FY26 Oper Cash Flow Growth Guidance to 13% to 14% Y/Y >CRM

Peer Comparison

Price change

Pliant Therapeutics Inc Forecast

Price Target

By TipRanks

96.08% upside

12 Months Forecast

Average 3 USD 96.08%

High 4 USD

Low 2 USD

Based on 4 Wall Street analysts offering 12 month price targets forPliant Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Pliant Therapeutics Inc - Dist in the past 3 months.

Technical Score

By Trading Central

1.43 / 1.6Support & Resistance

Recent bearish events outweigh bullish events.

There is one bearish event.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Pliant Therapeutics Inc

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.